Viscum ribosome inactivating protein

type 2 RIP of 264 aa, MW 60 kDa; viscotoxin is also available; ML1 binds B-galactosides, ML2 binds B-gal & NAG, ML3 binds N-acetyl-galactosides; aviscumine produced in E. coli via recombinant DNA

Also Known As:

Networked: 12 relevant articles (0 outcomes, 8 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Lentzen, Hans: 6 articles (01/2019 - 08/2008)
2.	Witthohn, Klaus: 4 articles (01/2014 - 09/2005)
3.	Mittelbronn, Michel: 3 articles (01/2019 - 02/2017)
4.	Naumann, Ulrike: 3 articles (01/2019 - 02/2017)
5.	Schötterl, Sonja: 3 articles (01/2019 - 02/2017)
6.	Schöffski, P: 3 articles (02/2015 - 12/2004)
7.	Wilhelm-Ogunbiyi, Karin: 3 articles (08/2008 - 09/2005)
8.	Huber, Stephan M: 2 articles (01/2019 - 01/2018)
9.	Fumoleau, P: 2 articles (02/2015 - 12/2004)
10.	Bergmann, Lothar: 2 articles (07/2011 - 08/2008)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2019 - "Despite not reaching statistical significance, a single intratumoral application of Aviscumine prolonged the median survival of GBM mice longer than tumor irradiation. " 10/04/2005 - "An immuno-polymerase chain reaction (IPCR) assay is used to evaluate the kinetic behaviour of the novel anti-cancer drug Aviscumine in plasma samples taken from 41 patients during a 3-year clinical trial. " 12/01/2004 - "Aviscumine was given twice weekly as a 1 h central i.v. infusion in patients with advanced, refractory progressive, solid malignant tumors who had not been previously exposed to natural mistletoe preparations. " 07/01/2011 - "This review explores the current knowledge base for aviscumine's mechanism of action, efficacy and side-effects in both preclinical studies and clinical trials, and it considers aviscumine's potential as a cancer therapy." 08/01/2008 - "Safety of aviscumine by subcutaneous route was assessed in patients with advanced cancer refractory to chemotherapy. "
2.	Glioma (Gliomas) 01/01/2018 - "The present study examined and compared the immunoboosting effects of three ML-1 containing drugs (the extract ISCADOR Qu, the recombinant ML-1 Aviscumine, and purified native ML-1) in the context of the T-cell mediated killing of glioma cells. " 02/01/2017 - "By microarray expression analysis, quantitative RT-PCR and RT-PCR based validation of microarray data we demonstrate for the Viscum album extract Iscador Qu and for the lectins Aviscumine and ML-1 that in glioma cells these drugs differentially modulate the expression of genes involved in the regulation of cell migration and invasion, including processes modulating cell architecture and cell adhesion. " 02/01/2015 - "Data were collected from two continual reassessment method (CRM) trials (T1: aviscumine in solid tumors with short time on treatment; T2: erlotinib + radiotherapy in brainstem gliomas with longer time on treatment) and one 3 + 3 design (T3: liposomal doxorubicin + cyclophosphamide combination in ovarian carcinoma). "
3.	Glioblastoma (Glioblastoma Multiforme) 01/01/2019 - "In this study our goal was to determine anticancer effects of the VE ISCADOR Qu, of recombinant ML-1 (Aviscumine), and of native ML-1 in the treatment of glioblastoma (GBM), the most common and highly malignant brain tumor in adults. " 01/01/2018 - "Treatment of glioblastoma (GBM) cells with ISCADOR Qu that contains a high ML concentration, but also viscotoxins and other compounds, as well as with Aviscumine or native ML-1, enhanced the expansion of cancer cell-specific T-cells as well as T-cell-mediated tumor cell lysis, but to a different degree. "
4.	Melanoma (Melanoma, Malignant) 01/01/2014 - "Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study." 01/01/2014 - "These results suggest that aviscumine may have a clinical impact in patients with previously treated metastatic melanoma and provide rationale for further clinical evaluation of this agent. " 01/01/2014 - "This phase II trial was conducted to test the efficacy and safety of aviscumine in patients with systemically pre-treated metastatic melanoma stage IV. A total of 32 patients with progressive stage IV melanoma after failure of standard therapy were enrolled onto a single-arm, multi-centre, open-label, phase II trial. "
5.	Carcinoma (Carcinomatosis) 02/01/2015 - "Data were collected from two continual reassessment method (CRM) trials (T1: aviscumine in solid tumors with short time on treatment; T2: erlotinib + radiotherapy in brainstem gliomas with longer time on treatment) and one 3 + 3 design (T3: liposomal doxorubicin + cyclophosphamide combination in ovarian carcinoma). "

Related Drugs and Biologics

1.	mistletoe lectin I
2.	viscum album peptide (Iscador)
3.	Cyclophosphamide (Cytoxan)
4.	Saporins
5.	Erlotinib Hydrochloride (CP 358,774)
6.	liposomal doxorubicin (Doxil)
7.	Lectins
8.	Ginsenosides
9.	Curcumin
10.	Homoharringtonine

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy
3.	Drug Therapy (Chemotherapy)